Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754219 | 0.92 | MEN1 (0.51) | MEN1KMT2A | |
| SCHEMBL7753274 | 0.91 | SMN1; SMN2 (0.55) | MEN1KMT2AKDM4EALDH1A1MAPK1 | |
| SCHEMBL6545433 | 0.91 | MAPK1 (0.58) | MEN1KMT2AALDH1A1MAPK1POLB | |
| SCHEMBL6546175 | 0.91 | PKM (0.55) | ALDH1A1PKM | |
| SCHEMBL7753921 | 0.88 | MEN1 (0.54) | MEN1KMT2A | |
| SCHEMBL7753891 | 0.87 | ABCB1 (0.57) | MEN1KMT2AKDM4EALDH1A1MAPK1 | |
| SCHEMBL7753266 | 0.82 | MEN1 (0.63) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL7752909 | 0.81 | MAPT (0.68) | MEN1KMT2AALDH1A1PKMMAPK1 | |
| SCHEMBL6812211 | 0.80 | CASP1 (0.57) | ALDH1A1PKMPOLB | |
| SCHEMBL6546363 | 0.80 | LMNA (0.64) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1068176-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | Jomaa, Hassan (DE) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000027803-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | JOMAA, HASSAN (DE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | MEN1 3863/4885KMT2A 1743/4885KDM4E 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.